# Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients

> **NCT03315923** · PHASE2,PHASE3 · COMPLETED · sponsor: **Isfahan University of Medical Sciences** · enrollment: 84 (actual)

## Conditions studied

- Secondary Progressive Multiple Sclerosis

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Glatiramer Acetate

## Key facts

- **NCT ID:** NCT03315923
- **Lead sponsor:** Isfahan University of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-01
- **Primary completion:** 2019-02-01
- **Final completion:** 2019-03-01
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2019-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03315923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03315923, "Comparison of Clinical Effects of Rituximab and Glatiramer Acetate in Secondary Progressive Multiple Sclerosis Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03315923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*